Navigation Links
Cyberonics Reports Strong Fiscal 2011 Third Quarter Results and Increases Guidance

HOUSTON, March 2, 2011 /PRNewswire/ -- Cyberonics, Inc. (Nasdaq: CYBX), a global leader in epilepsy management, today announced results for the quarter ended January 28, 2011.  

Quarterly HighlightsOperating results and achievements for the third quarter of fiscal 2011 compared to the third quarter of fiscal 2010 include:

  • Net sales increased by 15.3% to $47.1 million;
  • U.S. net sales increased by 24%;
  • U.S. epilepsy unit sales increased by 16%; and
  • Income from operations increased by 30% to $11.7 million.

  • "The third quarter of fiscal year 2011 was another successful quarter for our company, once again demonstrating consistent performance with year-over-year growth in worldwide net product sales attributable to the epilepsy indication increasing by more than 15%," commented Dan Moore, Cyberonics' President and Chief Executive Officer.  "We were particularly pleased with the robust 24% sales growth in our U.S. epilepsy business, which was driven by significantly higher volume and increased average selling prices.

    "Net sales in our international business were down 15% when compared with the third quarter of fiscal 2010, although the revenue of $7.1 million is consistent with last quarter.  Several of our international countries performed well during the quarter, however, execution challenges, combined with continuing economic difficulties in some markets, contributed to softness in some key EU countries.  We are increasing our efforts in these countries and expect to be in a position to restore growth in the next fiscal year.  In addition, we continue to make solid progress in Japan where we are focused on physician training and fulfilling patient registry requirements."

    The company reported net income of $7.2 million, or $0.25 per diluted share, for the third quarter of fiscal 2011 compared with net income of $8.8 million, or $0.29 cents per diluted share, in the third quarter of fiscal 2010.  The decline in net income for the quarter was attributable to an increase in the effective tax rate from 3% in fiscal 2010 to 38% in fiscal 2011.

    The company reported operating cash flow of $13.2 million for the quarter ended January 28, 2011.  Available cash balances were $85.3 million at quarter end, an increase of $17.4 million compared to the end of the second quarter of fiscal 2011.

    Moore concluded, "Operationally, this was another very strong quarter for Cyberonics.  We continue to emphasize profitability, as well as sustainable sales growth, as our primary goals, so we were very pleased to see income from operations increase by 30% this quarter to complement our 15% revenue growth.  Recently, we announced FDA approval of our fifth generation generator, the AspireHC™ high capacity generator, which is now in a limited market release.  This approval is further evidence of our product development progress and provides an important platform for future new product introductions, including the AspireSR™ generator with seizure response for which a European clinical trial is planned to start in the first half of calendar 2011.  We expect to continue to drive shareholder value through consistent execution, improved operating leverage and an expanded product portfolio."

    Fiscal 2011 GuidanceCyberonics is increasing its net sales guidance for fiscal year 2011 to the range of $189 million to $191 million on a constant currency basis, as compared to the previously provided range of $187 million to $190 million.  At current average rates, foreign currency exchange rate fluctuations are expected to have a minimal impact on revenue in fiscal 2011 compared to 2010.

    In addition, the company now expects that income from operations for fiscal year 2011 will be in the range of $47 million to $50 million, as compared to the previously provided range of $45 million to $48 million.

    Additional details will be provided during the upcoming conference call and in an investor presentation summarizing the company's fiscal year 2011 third quarter results, which is available in the investor relations section of Cyberonics' corporate website at

    Fiscal Year 2011 Third Quarter Results Conference Call InstructionsCyberonics will host a conference call today, March 2, 2011, beginning at 7:30 a.m. Central Time (8:30 a.m. Eastern Time) to review its results of operations for the third quarter of fiscal 2011 and future outlook, followed by a question and answer session.

    The conference call will be available to interested parties through a live audio webcast in the investor relations section of Cyberonics' corporate website at, where it will be archived and accessible for approximately 12 months.  To listen to the conference call live by telephone dial 877-638-4557 (if dialing from within the U.S.) or 914-495-8522 (if dialing from outside the U.S.).  The conference ID is 43242663.

    A replay of the conference call will be available approximately two hours after the completion of the conference call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing from outside the U.S.).  The replay conference ID access code is 43242663.  The replay will be available for one week on the above number.

    About Cyberonics, Inc. and the VNS Therapy® SystemCyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve.  Cyberonics markets the VNS Therapy System in selected markets worldwide.

    Additional information on Cyberonics and the VNS Therapy System is available at

    Safe harbor statementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words. Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning growth in sales and operating income in fiscal 2011, improving sales in key international markets, including EU countries and Japan, fulfilling regulatory obligations in Japan, achieving key product development milestones, including commencement of a clinical study for the AspireSR generator in the first half of calendar 2011, and fiscal 2011 guidance, as follows: sales of $189 million to $191 million, and operating income of $47 million to $50 million. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS therapy and sales of our products; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential patent infringement claims; potential litigation relating to compliance with laws and regulations pertaining to our business; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the potential identification of material weaknesses in our internal controls over financial reporting; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2010, and our Quarterly Reports on Form 10-Q for the fiscal quarters ended July 30, 2010, October 29, 2010 and January 28, 2011.Contact: Greg Browne ir@cyberonics.com281.228.7262CYBERONICS, INC. AND SUBSIDIARYCONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)For the Thirteen Weeks EndedFor the Thirty-Nine Weeks EndedJanuary 28, 2011January 22, 2010January 28, 2011January 22, 2010Net sales$




    120,040,684Cost of sales5,807,4024,952,63616,820,87415,410,492Gross Profit41,274,07435,868,640122,520,935104,630,192Operating Expenses:Selling, general and administrative22,078,06821,224,80165,374,03164,215,712Research and development7,494,8205,612,89920,989,58815,788,183Total Operating Expenses29,572,88826,837,70086,363,61980,003,895Income from Operations11,701,1869,030,94036,157,31624,626,297Interest income89,96317,237179,23983,004Interest expense(94,316)(297,143)(299,160)(1,230,676)Gain on early extinguishment of debt-846,01083,0743,042,477Other income (expense), net(51,801)(481,487)(383,595)344,308Income before income tax11,645,0329,115,55735,736,87426,865,410Income tax (benefit) expense4,453,060266,553(3,559,639)(39,993,170)Net income$




    66,858,580Basic income per share$




    2.42Diluted income per share$




    2.26Shares used in computing basic income per share28,121,85227,763,76827,949,25627,681,615Shares used in computing diluted income per share28,753,19728,145,06828,471,40328,810,757CYBERONICS, INC. AND SUBSIDIARYCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited except where indicated)January 28, 2011April 30, 2010(Audited)ASSETSCurrent AssetsCash and cash equivalents$


    59,229,911Restricted cash-1,000,000Accounts receivable, net23,715,44226,185,143Inventories15,726,81814,207,759Deferred tax assets14,522,63612,126,758Other current assets4,071,1132,495,019Total Current Assets143,309,730115,244,590Property and equipment, net8,282,2067,510,864Intellectual property, net4,810,9511,948,266Long-term investments5,134,795-Deferred tax assets44,855,89729,624,489Other assets1,072,6651,435,768Total Assets$


    155,763,977LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payables and accrued liabilities$


    23,325,253Convertible notes7,048,000-Total Current Liabilities26,966,26023,325,253Long-term liabilities:Convertible notes-15,460,000Deferred license revenue and other7,234,2136,119,077Total Long-Term Liabilities7,234,21321,579,077Total Liabilities34,200,47344,904,330Total Stockholders' Equity173,265,771110,859,647Total Liabilities and Stockholders' Equity$


    155,763,977CYBERONICS, INC. AND SUBSIDIARYCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)For the Thirty-Nine Weeks EndedJanuary 28, 2011January 22, 2010Cash Flow From Operating Activities:Net Income$


    66,858,580Non-Cash items included in Net Income:Gain on early extinguishment of debt(83,074)(3,042,477)Stock-base compensation4,752,1376,520,302Deferred income tax(4,422,670)(40,760,354)Unrealized gain in foreign currency transactions(623,980)(283,227)Other1,186,893792,762Changes in Operating Assets and Liabilities:Accounts receivable, net2,486,979(1,815,988)Inventories(1,465,189)(872,049)Other(4,030,294)118,364Net Cash Provided By Operating Activities37,097,31527,515,913Cash Flow From Investing Activities:Release of restricted cash1,000,000-Acquired intellectual property(3,245,000)(900,000)Purchases of property and equipment(2,794,256)(2,550,566)Investments in convertible debt securities(5,000,000)(100,000)Net Cash Used in Investing Activities(10,039,256)(3,550,566)Cash Flow From Financing Activities:Repurchase of convertible notes(8,241,260)(36,256,250)Proceeds from exercise of options for common stock14,390,448945,840Purchase of treasury stock(6,857,039)(37,551)Net Cash Used in Financing Activities(707,851)(35,347,961)Effect of Exchange Rate Changes on Cash and Cash Equivalents(306,398)(163,597)Net Increase (Decrease) in Cash and Cash Equivalents26,043,810(11,546,211)Cash and Cash Equivalents at Beginning of Period59,229,91166,225,479Cash and Cash Equivalents at End of Period$


    54,679,268CYBERONICS, INC. AND SUBSIDIARYTable of Sales Data(Unaudited)For the Thirteen Weeks EndedFor the Thirty-Nine Weeks EndedJanuary 28, 2011January 22, 2010January 28, 2011January 22, 2010US Units(1)1,9251,6675,8245,108US Revenue ($000s)$




    96,525International Units(1)6046991,8731,915International Revenue ($000s)$




    22,395TOTAL UNITS2,5292,3667,6977,023TOTAL REVENUE(2) ($000s)$




    118,920(1) Includes units sold for both epilepsy and depression indications(2) Excludes license revenue

    SOURCE Cyberonics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cyberonics Provides Update on Depression Post-Approval Study
    2. Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results
    3. Cyberonics Provides Update on Tax Position
    4. Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference
    5. Cyberonics Announces Epilepsy Technology Agreements
    6. Cyberonics Reports Strong Fiscal 2011 First Quarter Results
    7. Cyberonics to Participate in Upcoming September Investor Conferences
    8. Cyberonics Reports Inducement Equity Awards Under NASDAQ Listing Rule 5635(c)(4)
    9. Cyberonics Announces Conference Call to Discuss Fiscal Year 2011 Second Quarter Financial Results
    10. Cyberonics to Present at 22nd Annual Piper Jaffray Health Care Conference
    11. Cyberonics to Report Fiscal Year 2011 Third Quarter Results and Host Conference Call on March 2, 2011
    Post Your Comments:
    (Date:10/8/2015)... Oct. 8, 2015  Trovagene, Inc., (NASDAQ:   ... announced the presentation of results from a field ... Cancer Monitoring SM (PCM) platform to accurately ... physicians to determine appropriate therapy for patients. ... Trovagene is delivering the results today in an ...
    (Date:10/8/2015)... New York , October 8, 2015 ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - ... was valued at USD 2.63 billion in 2013 and is ... to 2022 to reach USD 4.00 billion in 2022. ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ...
    (Date:10/8/2015)... DUBLIN , Oct. 08 2015 /PRNewswire/ ... announced the addition of the "Natural ... Life Sciences Industry by Type (Rule-Based, Statistical, ... Europe, Asia-Pacific, Middle East and Africa, Latin ... report to their offering. --> ...
    Breaking Medicine Technology:
    ... 2011 Actavis Group, the international generic pharmaceuticals company, today ... a binding letter of intent (LOI) with QRxPharma Limited (ASX: ... United States.  Under the terms of the ... IR, a patented 3:2 ratio fixed dose combination of morphine ...
    ...  QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution ... for the formation of a strategic partnership to commercialise MoxDuo ... IR is a patented 3:2 ratio fixed dose combination of ... Group, hf a privately held company based in Europe with ...
    Cached Medicine Technology:
    (Date:10/10/2015)... , ... October 10, 2015 , ... The sixth annual ... on the growth of cybercrime costs for US companies. The New York Times broke ... 6th. With averages showing increases hovering around 20% among the companies surveyed, it only ...
    (Date:10/10/2015)... Arbor, MI (PRWEB) , ... October 10, 2015 , ... ... City, MO. , On the heels of the release of the Institute of ... of tools, and their integration with Cerner solutions that assist healthcare providers and consumers ...
    (Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
    (Date:10/9/2015)... ... October 09, 2015 , ... A new health tool ... Aid, is now available online ( ) – just in time for the ... officially begins in October. However, for many in the U.S., the real start of ...
    (Date:10/9/2015)... , ... October 09, 2015 , ... ... a special promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. ... are almost invisible against the teeth, which allow patients to complete treatment in ...
    Breaking Medicine News(10 mins):
    ... (HealthDay News) -- Drinking too much alcohol can lead to ... the most common cause of HIV infection and finding ways ... health efforts to prevent HIV/AIDS. Alcohol use has long ... whether unsafe sex associated with alcohol use actually led to ...
    ... MONDAY, Dec. 12 (HealthDay News) -- Breast cancer survivors ... treatment with radiation and/or chemotherapy, a new study says. ... and treatment-specific ways that these cancer therapies impair cancer ... Moffitt Cancer Center and Research Institute in Tampa, Fla., ...
    ... , Researchers at the Norwegian University of Life Sciences ... new method for detailed analyses of electrical activity in ... can help doctors and researchers to better interpret ... considerable steps forward in terms of interpreting for example ...
    ... has found that alcohol consumption directly impacts a person,s intention to ... the stronger becomes your intention to engage in unsafe sex. ... infection, and it is a main risk factor for the global ... prevent unsafe sex, HIV incidence in most high income countries (such ...
    ... leukemia patients, own infection-fighting cells appears to protect ... with fludarabine-based chemotherapy, according to new research from ... of Pennsylvania. The new process is a step ... from the commonly prescribed drug, which improves progression-free ...
    ... Researchers at the Stanford University School of Medicine report ... physical force contributes to scarring in mice. "Our ... the mechanical environment can directly increase inflammation, which is ... and associate chair of surgery. Mice genetically engineered ...
    Cached Medicine News:
    Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
    ... Distriman is a ... that is designed to ... used with Gilson DistriTip ... polypropylene syringes with level ...
    The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
    ... Plus, a handheld manual dispenser, is ideal ... long series pipetting. Its increased volume selection ... research tasks, and its smooth handling reduces ... The nine Combitips allow a wider range ...
    Medicine Products: